Omzo vs Willow: Clinician-Guided Compounded Care vs Structured Follow-Up
Quick verdict: Omzo focuses on clinician-guided access to compounded semaglutide and tirzepatide with medication costs disclosed as starting at $179 for semaglutide and $279 for tirzepatide, while Willow emphasizes an oral GLP-1 program priced from $299 that pairs telehealth with progress tracking and structured follow-up. Choose based on whether you prioritize compounded medication access and lower starting price or a structured digital follow-up model.
Explore Omzo clinician-guided plans
Omzo vs Willow: service model and clinical oversight
Both providers use licensed clinicians but they frame clinical care differently. Omzo connects users with licensed U.S. providers who review plans and may prescribe medication based on professional judgment. Omzo notes that providers make final determinations about prescribing and that the platform is not a medical practice. Willow is telehealth-first and states treatment is available only when a licensed clinician determines it is medically appropriate, with follow-up consultations included as part of a structured weight management journey.
See Willow telehealth program and follow-up
Five key differences that matter for most users
1. Medication format and sourcing
Omzo highlights compounded semaglutide and tirzepatide supplied through a compounded medication program produced by state-licensed sterile compounding pharmacies and notes these compounded drugs are not FDA-approved. Omzo also says clinicians may write prescriptions for branded medications but Omzo does not sell, dispense, or ship branded drugs. Willow promotes an oral GLP-1 program; its materials emphasize a structured program rather than a medication subscription. Willow also cautions that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable.
2. Pricing and starting costs
The sources list Omzo starting prices as $179 for semaglutide and $279 for tirzepatide. Willow lists a starting price of 299. Any additional membership, shipping, renewal, or pharmacy costs are not detailed in the captured Willow content. Omzo states medication costs are included in fees collected by Omzo and Omzo pays the pharmacies, but Omzo also warns pricing, eligibility, pharmacy, state coverage and renewal terms may change.
3. Program focus and support
Willow positions its offering as a structured weight management journey with progress tracking tools and follow-up consultations intended to convert GLP-1 efficacy into sustainable results. Omzo emphasizes clinician-guided GLP-1 care with fast, discreet delivery and notes FSA and HSA eligibility, focusing primarily on access to compounded and prescription options through clinician review.
4. Regulatory and safety language
Omzo repeatedly states that compounded medications are not FDA-approved and have not been evaluated by FDA for safety, effectiveness, or quality. Willow captured text advises confirming medication-specific approval status and notes that branded and compounded products are not interchangeable. Both sources make clinician review and appropriateness central to access.
5. Eligibility and prescribing discretion
Both sources indicate that licensed clinicians determine eligibility. Omzo stresses that providers make the final determination and that the Omzo assessment does not create a doctor patient relationship. Willow says treatment is available only when a licensed clinician determines it is medically appropriate.
Comparison table: Omzo vs Willow
| Criteria | Omzo | Willow |
|---|---|---|
| Starting price | $179 semaglutide; $279 tirzepatide | 299 |
| Medication format | Compounded semaglutide and tirzepatide; providers may prescribe branded meds but Omzo does not dispense them | Oral GLP-1 program |
| Clinical model | Clinician-guided plans reviewed by licensed U.S. providers; providers make final prescribing decisions | Telehealth-first with licensed telehealth team and follow-up consultations |
| Support and tracking | Fast, discreet delivery; clinician guidance noted | Progress tracking tools and structured follow-up to support long-term outcomes |
| Regulatory note | Compounded medications are not FDA-approved and not reviewed by FDA for safety, effectiveness or quality | Medication-specific approval status must be confirmed; branded and compounded products are not interchangeable |
Practical considerations from the captured facts
If your priority is access to compounded weekly injectables at a lower listed starting price and you accept that compounded drugs are not FDA-approved, Omzo presents a clinician-guided path with medication costs shown for semaglutide and tirzepatide and with medication fees included in Omzo’s collected fees. If you want an oral GLP-1 regimen wrapped in progress tracking and structured follow-up, and you value a program oriented around behavior change, Willow positions itself around that model with an entry price listed as 299.
Compare Omzo medication options
Review Willow follow-up features
Conclusion: Choose based on what matters most
Choose Omzo if you want clinician-guided access to compounded semaglutide or tirzepatide with listed starting prices of $179 and $279 respectively, and if you accept that compounded medications are not FDA-approved and that providers make final prescribing decisions. Choose Willow if you prefer an oral GLP-1 program built around telehealth, progress tracking, and structured follow-up, with a listed starting price of 299 and treatment available only when a licensed clinician determines it is medically appropriate.